{
    "clinical_study": {
        "@rank": "70443", 
        "arm_group": [
            {
                "arm_group_label": "Famitinib", 
                "arm_group_type": "Experimental", 
                "description": "Famitinib 25 mg qd p.o., 6 weeks per cycle.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent."
            }, 
            {
                "arm_group_label": "Sunitinib", 
                "arm_group_type": "Active Comparator", 
                "description": "Sunitinib 50 mg qd p.o., 4 weeks out of 6.The treatment continued until disease progression or intolerable toxicity happened or patients withdrawal of consent."
            }
        ], 
        "brief_summary": {
            "textblock": "-  Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1\n           and Flt3. Phase I study has shown that the toxicity is manageable.\n\n        -  The purpose of this study is to compare the efficacy and safety profile between\n           Famitinib and Sunitinib in patients with metastatic renal cell carcinoma."
        }, 
        "brief_title": "A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Renal Cell Cancer", 
            "Metastatic Renal Cell Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Carcinoma, Renal Cell"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with histologically confirmed advanced renal cell carcinoma including clear\n             cell component and not available for surgery\n\n          -  First-line therapy or second-line treatment (second-line treatment e.g chemotherapy\n             or cytokine therapy as first-line treatment failure or resistant patients)\n\n          -  With measurable disease (using RECIST1.0 standard conventional CT scan \u2265 20 mm,\n             spiral CT scan \u2265 10mm, target lesion did not receive radiation therapy, cryotherapy)\n\n          -  Male or female, age \u226518 and \u226475\n\n          -  ECOG 0-1\n\n          -  Life expectancy \u2265 3 months\n\n          -  Subjects received surgery, chemotherapy, radiation therapy, cytokines treatment\n             caused the damage has been restored, the time interval \u2265 4 weeks, and the wound has\n             completely healed\n\n          -  Normal major organ function\n\n          -  Signed and dated informed consent\n\n        Exclusion Criteria:\n\n          -  Previously received targeted therapy of the metastatic renal cell carcinoma (such as\n             sunitinib, Sorafenib)\n\n          -  Past or suffering from other cancer, but other than cure basal cell carcinoma and\n             cervical carcinoma in situ\n\n          -  Participated in other clinical trials  within four weeks\n\n          -  A variety of factors that affect the oral medication (such as inability to swallow,\n             gastrointestinal resection, chronic diarrhea and intestinal obstruction)\n\n          -  Known brain metastases, spinal cord compression, cancer, meningitis, or screening CT\n             or MRI examination revealed brain or leptomeningeal disease\n\n          -  Patients with hypertension (systolic blood pressure> 140 mmHg, diastolic blood\n             pressure> 90 mmHg). Patients with more than Class I, myocardial ischemia or\n             myocardial infarction, arrhythmia (including QT interval \u2265 440ms) and class I heart\n             failure.\n\n          -  Urine protein \u2265 + + and confirmed the 24-hour urinary protein>1.0 g\n\n          -  Coagulopathy with bleeding tendency (such as active peptic ulcer) or are receiving\n             thrombolytic or anticoagulant therapy\n\n          -  Previous hyperactivity / venous thromboembolic events, such as cerebrovascular\n             accident (including transient ischemic attacks), deep vein thrombosis and pulmonary\n             embolism\n\n          -  The preexisting abnormal thyroid function, even in the case of medication still can\n             not be maintained within the normal range\n\n          -  With a history of abuse of psychotropic drugs or mental disorders\n\n          -  Patients with Hepatitis B or Hepatitis C\n\n          -  History of immunodeficiency, including HIV testing positive or suffering from\n             acquired, congenital immunodeficiency disease, or a history of organ transplantation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829841", 
            "org_study_id": "FMTN-II-MRCC"
        }, 
        "intervention": [
            {
                "arm_group_label": "Famitinib", 
                "description": "Famitinib 25 mg p.o. qd", 
                "intervention_name": "Famitinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sunitinib", 
                "description": "Sunitinib 50 mg p.o. qd", 
                "intervention_name": "Sunitinib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Sunitinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "MRCC", 
            "Metastatic Renal Cell Cancer", 
            "Famitinib", 
            "Sunitinib"
        ], 
        "lastchanged_date": "April 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100021"
                }, 
                "name": "Cancer Institute and Hospital Chinese Academy of Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Positive-controlled, Double-blind, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced Metastatic Renal Cell Cancer", 
        "other_outcome": {
            "measure": "body vitals, laboratory parameters", 
            "safety_issue": "Yes", 
            "time_frame": "3 years"
        }, 
        "overall_official": [
            {
                "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
                "last_name": "Jinwan Wang, M.D", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
                "last_name": "Jianhui Ma, M.D", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Objective Response Rate", 
            "safety_issue": "No", 
            "time_frame": "18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829841"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progress free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Disease Control Rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Overall Survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "42-day cycle visit until disease progress"
            }, 
            {
                "measure": "Number of Participants with Adverse Events as a Measure of Safety", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Jiangsu HengRui Medicine Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Jiangsu HengRui Medicine Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}